{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:30:48Z","timestamp":1789576248649,"version":"build-2803163510"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014882","name":"Department of Finance of Hebei","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this study was to conduct a bibliometric analysis of the relevant literature on Duchenne muscular dystrophy (DMD) to ascertain its current status, identify key areas of research and demonstrate the evolution of the field.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The analysis sourced documents from the Science Citation Index Expanded in the Web of Science core collection, utilizing CiteSpace software and an online bibliometric platform to analyze collaborative networks among authors, institutions and countries, and to map out the research landscape through journal and reference evaluations. Keyword analyses, including clustering and emergent term identification, were conducted, alongside the development of knowledge maps.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 9,277 documents, indicating a rising publication trend in the field. The Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale emerged as the top publishing institution, with Francesco Muntoni as the most prolific author. The United States dominated in publication output, showcasing significant leadership. The keyword analysis highlighted 786 key emergent terms, primarily focusing on the mechanisms, diagnostics and treatment approaches in DMD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The field of DMD research is experiencing robust growth, drawing keen interest globally. A thorough analysis of current research and trends is essential for advancing knowledge and therapeutic strategies in this domain.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1429609","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T05:10:25Z","timestamp":1732770625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Research hotspots and trends for Duchenne muscular dystrophy: a machine learning bibliometric analysis from 2004 to 2023"],"prefix":"10.3389","volume":"15","author":[{"given":"Pingping","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongran","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy. Nature reviews","volume":"7","author":"Duan","year":"2021","journal-title":"Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00185-4","article-title":"Cell therapy for patients with Duchenne muscular dystrophy","volume":"399","author":"Davis","year":"2022","journal-title":"Lancet(London,England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann Phys Rehabil Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: A randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/02692155221095491","article-title":"The effect of aerobic training on motor function and muscle architecture in children with Duchenne muscular dystrophy: A randomized controlled study","volume":"36","author":"Bulut","year":"2022","journal-title":"Clin Rehabil"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21270","article-title":"Aquatic therapy for children with Duchenne muscular dystrophy: a pilot feasibility randomised controlled trial and mixed-methods process evaluation","volume":"21","author":"Hind","year":"2017","journal-title":"Health Technol Assess (Winchester England)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"B11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J rare Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet (London England)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscular disorders: NMD"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11069-014-1260-y","article-title":"An overview of climate change vulnerability: A bibliometric analysis based on web of science database","volume":"74","author":"Wang","year":"2014","journal-title":"Nat Hazards"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307509100","article-title":"Mapping knowledge domains: characterizing PNAS","author":"Boyack","year":"2004","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-017-9711-0","article-title":"Research trends and hotspots related to ammonia oxidation based on bibliometric analysis","volume":"24","author":"Zheng","year":"2017","journal-title":"Environ Sci pollut Res Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s11629-018-5280-z","article-title":"Visual analysis of the evolution and focus in landslide research field","volume":"16","author":"Yang","year":"2019","journal-title":"JMtSci-Engl"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/asi.20317","article-title":"Citespace ii: detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Of Am Soc Inf Sci Technol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/2050312118800199","article-title":"Knowledge mapping of medication literacy study: A visualized analysis using CiteSpace","volume":"6","author":"Liang","year":"2018","journal-title":"SAGE Open Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-020-01312-w","article-title":"Global scientific output trend for Akkermansia muciniphila research: a bibliometric and scientometric analysis","volume":"20","author":"Dehghanbanadaki","year":"2020","journal-title":"BMC Med Inf decision making"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s42836-020-00039-3","article-title":"Global research status and trends of UKA for knee osteoarthritis: a bibliometric analysis","volume":"2","author":"Liu","year":"2020","journal-title":"Arthroplasty (London England)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s41016-021-00264-y","article-title":"Bibliometric analysis of China\u2019s contribution to the knowledge system of cerebrovascular intervention","volume":"7","author":"Ma","year":"2021","journal-title":"Chin neurosurgical J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2018.01.001","article-title":"Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy. Consenso para el diagn\u00f3stico, tratamiento y seguimiento del paciente con distrofia muscular de Duchenne","volume":"34","author":"Nascimento Osorio","year":"2019","journal-title":"Neurologia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/genes11080837","article-title":"Therapeutic strategies for duchenne muscular dystrophy: an update","volume":"11","author":"Sun","year":"2020","journal-title":"Genes"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000739","article-title":"Update in Duchenne and Becker muscular dystrophy","volume":"32","author":"Waldrop","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/molecules201018168","article-title":"Duchenne muscular dystrophy: from diagnosis to therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules (Basel Switzerland)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14712598.2022.2150543","article-title":"Biological and genetic therapies for the treatment of Duchenne muscular dystrophy","volume":"23","author":"Wilton-Clark","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-0333D","article-title":"Rehabilitation management of the patient with duchenne muscular dystrophy","volume":"142","author":"Case","year":"2018","journal-title":"Pediatrics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"New Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet (London England)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet (London England)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"van Deutekom","year":"2007","journal-title":"New Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Sci (New York N.Y.)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/s1474-4422(03)00382-x","article-title":"Novel therapies for Duchenne muscular dystrophy","volume":"2","author":"Kapsa","year":"2003","journal-title":"Lancet Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"2016","author":"Matthews","year":"2016","journal-title":"Cochrane Database systematic Rev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy","volume":"8","author":"McGreevy","year":"2015","journal-title":"Dis Models Mech"},{"key":"B42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0074-7696(08)60158-8","article-title":"Characteristics of skeletal muscle in mdx mutant mice","volume":"191","author":"De la Porte","year":"1999","journal-title":"Int Rev cytology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.20602","article-title":"Satellite cells from dystrophic (mdx) mice display accelerated differentiation in primary cultures and in isolated myofibers","volume":"235","author":"Yablonka-Reuveni","year":"2006","journal-title":"Dev dynamics: an Off Publ Am Assoc Anatomists"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1023\/a:1005545325254","article-title":"Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse","volume":"20","author":"Gillis","year":"1999","journal-title":"J Muscle Res Cell Motil"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.151.6.1321","article-title":"Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology","volume":"151","author":"Chen","year":"2000","journal-title":"J Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.240335297","article-title":"Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model","volume":"97","author":"Wang","year":"2000","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B47","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nm897","article-title":"Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse","volume":"9","author":"Lu","year":"2003","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts skeletal muscle signaling: roles of ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36612","article-title":"Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy","volume":"119","author":"Lai","year":"2009","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Sci (New York N.Y.)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet (London England)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy. Nature reviews","volume":"15","author":"Verhaart","year":"2019","journal-title":"Neurology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J rare Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: A nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.120","article-title":"Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice","volume":"16","author":"Jearawiriyapaisarn","year":"2008","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21627","article-title":"Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs","volume":"65","author":"Yokota","year":"2009","journal-title":"Ann Neurol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","article-title":"Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B61","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2015-103387","article-title":"The importance of genetic diagnosis for Duchenne muscular dystrophy","volume":"53","author":"Aartsma-Rus","year":"2016","journal-title":"J Med Genet"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/15519","article-title":"Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses","volume":"23","author":"C\u00f4t\u00e9","year":"1999","journal-title":"Nat Genet"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"New Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2250","article-title":"Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy","volume":"23","author":"Restrepo-Cordoba","year":"2021","journal-title":"Eur J Heart failure"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.11.004","article-title":"Cardiovascular disease in duchenne muscular dystrophy: overview and insight into novel therapeutic targets","volume":"7","author":"Schultz","year":"2022","journal-title":"JACC. Basic to Trans Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The Pathogenesis and Therapy of Muscular Dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Sci (New York N.Y.)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Sci (New York N.Y.)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1429609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T05:10:30Z","timestamp":1732770630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1429609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2024.1429609"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1429609","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"article-number":"1429609"}}